<DOC>
	<DOCNO>NCT00270881</DOCNO>
	<brief_summary>The primary purpose study evaluate safety efficacy cord blood transplantation adult patient hematologic malignancy include refractory acute leukemia . The transplant procedure determine detail accord previously publish report show high survival , investigator could expect similar result .</brief_summary>
	<brief_title>Safety Efficacy Unrelated Cord Blood Transplantation Adult Patients With Hematologic Malignancies</brief_title>
	<detailed_description>Although cord blood consider alternative donor source allogeneic hematopoietic stem cell transplantation , procedure yet standardize . Recently , single institute result cord blood transplantation adult patient hematologic malignancy report Takahashi et al ( Blood 2004:104 ; 3813-3820 ) , survival significantly good bone marrow transplantation unrelated donor . The purpose study reevaluate safety efficacy cord blood transplantation adult patient hematologic malignancy use transplant procedure multi-institutional setting .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Clinical diagnosis acute leukemia , chronic myelogenous leukemia , myelodysplastic syndrome Lack HLAidentical 1 locus mismatch related donor Age 20 , 55 Performance status 0 1 No moderate sever organ dysfunction ( liver , kidney , heart , lung ) No antiHLA antibody Informed consent obtain Uncontrollable diabetes Uncontrollable hypertension Active infection TPHA , HBsAg , HCVAb positive HTLVI , HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>cord blood transplantation</keyword>
	<keyword>myeloablative regimen</keyword>
	<keyword>hematologic malignancy</keyword>
</DOC>